{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:06:56Z","timestamp":1787242016427,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T00:00:00Z","timestamp":1241481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00417-009-1099-1","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T17:02:10Z","timestamp":1241456530000},"page":"1375-1382","source":"Crossref","is-referenced-by-count":153,"title":["Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin\u00ae) eye drops against corneal neovascularization"],"prefix":"10.1007","volume":"247","author":[{"given":"Yanyan","family":"Koenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Cursiefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,5]]},"reference":[{"key":"1099_CR1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","volume":"12","author":"JH Chang","year":"2001","unstructured":"Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242\u2013249, doi: 10.1097\/00055735-200108000-00002","journal-title":"Curr Opin Ophthalmol"},{"key":"1099_CR2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","volume":"104","author":"F Bock","year":"2007","unstructured":"Bock F, Koenig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336\u2013344, doi: 10.1007\/s00347-007-1512-2","journal-title":"Ophthalmologe"},{"key":"1099_CR3","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","volume":"103","author":"C Cursiefen","year":"2006","unstructured":"Cursiefen C, Chen L, Saint-Geniez M et al (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 103:11405\u201311410, doi: 10.1073\/pnas.0506112103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1099_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249\u2013257, doi: 10.1038\/35025220","journal-title":"Nature"},{"key":"1099_CR5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487, doi: 10.1056\/NEJM199412013312203","journal-title":"N Engl J Med"},{"key":"1099_CR6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","volume":"26","author":"E Yoeruek","year":"2007","unstructured":"Yoeruek E, Spitzer MS, Tatar O et al (2007) Safety profile of Bevacizumab on cultured human corneal cells. Cornea 26:977\u2013982, doi: 10.1097\/ICO.0b013e3180de1d0a","journal-title":"Cornea"},{"key":"1099_CR7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, Koenig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281\u2013284, doi: 10.1007\/s00417-007-0684-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1099_CR8","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","volume":"115","author":"SW Kim","year":"2008","unstructured":"Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical Bevacizumab on corneal neovascularization. Ophthalmology 115:e33\u2013e38, doi: 10.1016\/j.ophtha.2008.02.013","journal-title":"Ophthalmology"},{"key":"1099_CR9","first-page":"2514","volume":"41","author":"W Philipp","year":"2000","unstructured":"Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514\u20132522","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1099_CR10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","volume":"19","author":"C Cursiefen","year":"2000","unstructured":"Cursiefen C, Rummelt C, K\u00fcchle M (2000) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19:526\u2013533. doi: 10.1097\/00003226-200007000-00025","journal-title":"Cornea"},{"key":"1099_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/PL00000615","volume":"56","author":"JP Irigoyen","year":"1999","unstructured":"Irigoyen JP, Mo\u00f1oz-C\u00e1noves P, Montero L et al (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104\u2013132, doi: 10.1007\/PL00000615","journal-title":"Cell Mol Life Sci"},{"key":"1099_CR12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0037-1615846","volume":"82","author":"F Blasi","year":"1999","unstructured":"Blasi F (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82:298\u2013304","journal-title":"Thromb Haemost"},{"key":"1099_CR13","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545\u20132552, doi: 10.1167\/iovs.06-0570","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1099_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","volume":"9","author":"NH Fernando","year":"2004","unstructured":"Fernando NH, Hurwitz HI (2004) Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9:11\u201318, doi: 10.1634\/theoncologist.9-suppl_1-11","journal-title":"Oncologist"},{"key":"1099_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372, doi: 10.1016\/j.ophtha.2005.11.019","journal-title":"Ophthalmology"},{"key":"1099_CR16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.expneurol.2004.01.022","volume":"187","author":"JM Krum","year":"2004","unstructured":"Krum JM, Rosenstein JM (2004) New roles for VEGF in nervous tissue: beyond blood vessels. Exp Neurol 187:246\u2013253, doi: 10.1016\/j.expneurol.2004.01.022","journal-title":"Exp Neurol"},{"key":"1099_CR17","first-page":"323","volume":"31","author":"G Soubrane","year":"1990","unstructured":"Soubrane G, Jerdan J, Karpouzas I et al (1990) Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 31:323\u2013333","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1099_CR18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exer.2008.08.007","volume":"87","author":"F Bock","year":"2008","unstructured":"Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C (2008) Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 87:462\u2013470, doi: 10.1016\/j.exer.2008.08.007","journal-title":"Exp Eye Res"},{"key":"1099_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.87.1.101","volume":"87","author":"C Cursiefen","year":"2003","unstructured":"Cursiefen C, Rummelt C, K\u00fcchle M, Schl\u00f6tzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101\u2013106, doi: 10.1136\/bjo.87.1.101","journal-title":"Br J Ophthalmol"},{"key":"1099_CR20","unstructured":"Sadrai Z, Dastjerdi MH, Saban DR, Dana R (2008) Corneal penetration of topical bevacizumab (Avastin). ARVO poster, 2008."},{"issue":"8","key":"1099_CR21","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","volume":"45","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Cao J, Chen L et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666\u20132673, doi: 10.1167\/iovs.03-1380","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1099_CR22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","volume":"126","author":"BO Bachmann","year":"2008","unstructured":"Bachmann BO, Bock F, Wiegand SJ et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126(1):71\u201377, doi: 10.1001\/archopht.126.1.71","journal-title":"Arch Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1099-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1099-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:47Z","timestamp":1559058047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1099-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,5]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1099-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,5]]}}}